VC Deals
Apitope, a Belgium-based drug developer focused on “treating the underlying cause of autoimmune diseases,” has raised €12 million in Series B funding.Wales Life Sciences Fund led the round, and was joined by Vesalius Biocapital, LRM, PMV and Wyvern
PhageTech Inc., an Irvine, Calif.-based developer of biosensors for the early detection of cancers, has raised $2.4 million in Series A funding co-led by Mark IV Capital and Black River Investments
BeneStream, a New York-based company that moves qualified employees onto free government health insurance, has raised $2 million in new Series A funding from BlueCross BlueShield Venture Partners and Sandbox Advantage Fund. The round total is now $6.26 million
Therachon, a France-based developer of therapies for achondroplasia, has raised $35 million in Series A funding. OrbiMed led the round, and was joined by New Enterprise Associates and return backers Inserm Transfert Initiative and Versant Ventures
Neuromod Devices Ltd., a Dublin-based developer of medical devices to treat chronic tinnitus, has raised €5.5 million in Series A funding from Fountain Healthcare Partners
Encycle Therapeutics Inc., a Toronto-based developer of “drug-like cyclic peptides,” has raised C$2.85 million in new VC funding. Takeda Ventures led the round, and was joined by Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund
Neon Therapeutics, a Cambridge, Mass.-based developer of neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has raised $55 million in first-round funding. Third Rock Ventures led the round, and was joined by Clal Biotechnology Industries and Access Industries
Elcelyx Therapeutics, a San Diego-based developer of drugs for diabetes and weight loss, has raised $40 million in Series E funding. Sailing Capital led the round, and was joined by Clough Capital Partners and return backers Morgenthaler Ventures, Kleiner Perkins Caufield & Byers, Technology Partners and GSM Fund
Euroscreen, a Belgium-based drug developer initially focused on women’s health, has raised €16 million in Series B funding. SFPI-FPIM was joined by Fund+, Capricorn Health-Tech Fund and return backers Vesalius Biocapital II Partners, SRIW SA and BNP Paribas Fortis Private Equity
UE LifeSciences, a six-year-old Philadelphia, Pa.-based health technology developer, has raised $3 million in Series A funding led by Aarin Capital, with participation from Unitus Seed Fund
Corvus Pharmaceuticals, a 1.5-year-old, Burlingame, Ca.-based immuno-oncology startup, has raised $75 million in Series B funding, according to an SEC filing first flagged by Silicon Valley Business Journal. Prior to this round, the company had raised $33.5 million in Series A funding led by OrbiMed Advisors, with participation from Adams Street Partners and Novo Ventures
PE Deals
Apax Partners has agreed to acquire an undisclosed stake in Ideal Protein, a Canada-based weight loss and wellness solutions company. No financial terms were disclosed
Johnson & Johnson (NYSE: JNJ) completed its previously-announced sale of the Splenda sweetener business to Carmel, Ind.-based Heartland Food Products Group, which was sponsored on the deal by Centerbridge Partners. No financial terms were disclosed, except that Splenda generated around $370 million in 2014 sales
Advanced Dermatology & Cosmetic Surgery, a Maitland, Fla.-based portfolio company of Audax Group, has acquired the assets of Dermatology of Northern Colorado, a dermatology practice in Fort Collins, Colorado. No financial terms were disclosed. Audax said it was the firm’s 500th completed acquisition
Spring & Sprout Dental Holdings, a Dundee, Mich.-based portfolio company of Huron Capital Partners, has acquired Rising Stars Pediatric Dentistry(Austin, Texas) for an undisclosed amount
Trust Healthcare Consulting Services, a Springfield, Mo.-based provider of outsourced coding and health information management consulting services to the medical sector, has secured an undisclosed amount of equity funding from MTS Health Investors
AMO Pharma Ltd., a pharma developer focused on rare diseases, has raised $25 million in private equity funding from Woodford Investment Management. The company has offices in London and Philadelphia
Epic Health Services Inc., a Dallas-based provider of pediatric skilled nursing and therapy, has acquiredUnifour Nursing, a Newton, N.C.-based provider of pediatric and adult home care services. No financial terms were disclosed. EHS is a portfolio company of Webster Capital
IPO Deals
MyoKardia Inc., a South San Francisco-based provider of therapies for genetic heart disease, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol MYOK, with Credit Suisse and Cowen & Co. serving as lead underwriters. The company reports a $12.2 million net loss on $7.1 million in collaboration and license revenue for the first half of 2015. It has raised over $90 million in VC funding, from firms like Third Rock Ventures (52.67% pre-IPO stake), Fidelity (13.19%), Aventis Inc. (11.22%), Casdin Capital, Cormorant Asset Management, Perceptive Life Sciences and BioBridge
NeuroSigma Inc., a Los Angeles-based developer of bioelectronic products to treat people suffering from major neurological and neuropsychiatric disorders such as epilepsy and depression, has withdrawn registration for a $50 million IPO. The company originally filed its S-1 in August 2014, and did not provide a reason for its withdrawal. Jefferies had been listed as lead underwriter
Edge Therapeutics, a Berkeley Heights, N.J.-based developer of therapies for life-threatening neurological conditions, raised $80 million in its IPO. The company priced 7.3 million shares at $11 per share, compared to plans to offer 5.67 million shares at between $14 and $16 per share. Its initial market cap is $284 million, and the pre-revenue company will trade on the Nasdaq under ticker symbol EDGE. Leerink Partners and Credit Suisse served as co-lead underwriters. Edge Therapeutics has raised just over $100 million in VC funding, from firms like Sofinnova Ventures (9.2% pre-IPO stake), Venrock (8%), Janus Capital Management (8%), New Leaf Venture Partners (6.4%), Franklin Templeton (6.4%) and BioMed Ventures
Mirna Therapeutics Inc., an Austin, Texas-based developer of microRNA therapeutics for oncology, raised $44 million in its IPO. The company priced 6.3 million shares at $7 per share, compared to plans to offer 4.65 million shares at between $13 and $15 per share. Its initial market cap is around $140 million. The pre-revenue company will trade on the Nasdaq under ticker symbol MIRN, while Citigroup and Leerink Partners served as co-lead underwriters. Mirna Therapeutics had raised around $83 million in VC funding, from firms like Sofinnova Ventures (17.83% pre-IPO stake), New Enterprise Associates (17.83%), Pfizer Ventures (15.01%), Eastern Capital (6.39%), Osage University Partners and Correlation Ventures
Surgery Partners Inc., a Nashville, Tenn.-based surgical facilities operator backed by H.I.G. Capital, raised $271 million in its IPO. The company priced 14.29 million shares at $19 per share (below $23-$26 per share range), for an initial market cap of around $915 million. It will trade on the Nasdaq under ticker symbol SGRY, while BofA Merrill Lynch, Goldman Sachs and Jefferies served as lead underwriters. Surgery Partners reports $23 million of net income on $457 million in revenue for the first six months of 2015, compared to $9 million of net income on $147 million in revenue for the year-earlier period
Advanced Accelerator Applications SA, a French developer of molecular imaging and molecular therapy products, has filed for a $75 million IPO. The company previously filed for a $100 million IPO in November 2014, but withdrew the registration this past February. It again plans to trade on the Nasdaq under ticker symbol AAAP, with Citigroup and Jefferies serving as lead underwriters. Shareholders include HBM Healthcare Investments (9.4% pre-IPO stake)
Other Deals
Access Integrated Healthcare, a Los Angeles-based healthcare services organization focused on the workers’ compensation and personal injury sectors, has secured a $50 million senior credit facility from Victory Park Capital
Sources: Term Sheet, Financial Times, StrictlyVC, TechinAsia, CrunchBase, TechCrunch, Bloomberg
#healthtech #asia